Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

SDĚLENÍ

Ministerstva zahraničních xxxx,

xxxxxx xx xxxx a xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 1. října 2023 bylo xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx nového znění Xxxxxxx X - Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xxx rok 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx.

X xxxxx zněním Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x prezident republiky xxxxxxxx xxxxxxx x xxxxxxx xxxx Přílohy X Českou xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, pro Xxxxxx republiku vstoupilo x xxxxxxxx xxx 18. xxxxxx 2024 x xxxxxxxxx Přílohu X xxx xxx 2023, xxxxxxx od 1. xxxxx 2023, xxxxx xxxxxxxxx v xxxxxxxx xxx Českou xxxxxxxxx dne 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.

Xxxxxxxx znění Xxxxxxx X pro xxx 2024 x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. XXXx. Xxxxxx, Ph.D., LL.M., x. x.

xxxxxx xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;

Xxxxxxx č. 1

Xxxxxxx xxxxxxxxxxx smlouvy xx xxxxxxx jazyka

Úvod

Seznam zakázaných xxxxx x metod xxxxxxx je xxxxxxx Xxxxxxxxxxx standard x xxxxx Světového antidopingového xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx zakázaných xxxxx x xxxxx bude xxxxxxxxx XXXX x xxxx publikován x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxx x francouzským textem xxxxxxxxx xxxxx x xxxxxxxxxx.

Xxxx xxxx uvedeny xxxxxxx pojmy xxxxxxxxx x xxxxx Xxxxxxx xxxxxxxxxx látek a xxxxx.

Xxxxxxxx Xxx soutěži

Pokud XXXX xxx xxxx xxxxx xxxxxxxxxxx jiné xxxxxx, je xxxxxx Xxx soutěži v xxxxxx xxxxxxx xxxxxxxxxxx xxxxx před půlnocí (xx 23:59 xxxxx) x xxx předcházející Xxxxxxx, xxxxx xx xx Xxxxxxxxx zúčastnit, xx xx konce Xxxxxxx x procesu xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, xx xxxx xxxxx xxxx metoda xx zakázána Při xxxxxxx x Mimo xxxxxx, xxx xx xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Nespecifické

Podle článku 4.2.2 Světového antidopingového Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx látkami, x xxxxxxxx xxxx xxxxxxxxxx x Seznamu xxxxxxxxxx xxxxx a xxxxx xxxxxxx. Xxxxx Xxxxxxxx metoda xxxxxx Xxxxxxxxxxx metodou, xxxxx xxxx v Xxxxxxx xxxxxxxxx označena xxxx Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx x xxxxxx „Xxxxxxxxxx xxxxx a Xxxxxxxxxx xxxxxx xxxxxxx x xxxxxx 4.2.2 xx xxxxxx být xxxxxx xxxxxxxx považovány xx xxxx xxxxxxxx xxxx xxxx xxxxxxxxxx xxx jiné xxxxxxxxx xxxxx xxxx xxxxxx. Xxx spíše o xxxxx a xxxxxx, xxxxx Sportovec pravděpodobně xxxx nebo xxxxxx x xxxxxx xxxxx xxx ke xxxxxxxx xxxxxxxxxxx výkonu.“

Návykové látky

Podle xxxxxx 4.2.3 Xxxxxx xxxx Návykové xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx xxxx xxxx xxxxxx označeny x xxxxxx xxxxxx xxxxxxx xxxxxxxxxx ve společnosti xxxx xxxxx xxxxxx. Xxxx Xxxxxxxx xxxxx xxxx označovány tyto xxxxx: kokain, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 NESCHVÁLENÉ XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Specifické látky.

Jakákoliv xxxxxxxxxxxxxx xxxxx, xx xxxxxx se nevztahuje xxxxx x následujících xxxxxx Xxxxxxx x xxxxx není x xxxxxxxx xxxx schválena xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx pro xxxxxxx použití x xxxx (např. xxxxxx x xxxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxx xxxxxxx vývoj xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx stále.

Tato xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-dinitrofenol (XXX) a xxxxxxxxxx xxxxxxxxx (např. Xxxxxxxxxxx x Tirasemtiv).

S1 XXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Nespecifické xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX STEROIDY (XXX)

Xxx xxxxxxxxx podání, xxxx jiné včetně:

•	1-androstenediol (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on)		•	mesterolon
•	4-androstenediol (androst-4-en-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on)
•	4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on)		•	metenolon
•	5-androstenedion (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (metyltrienolon, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol)		•	norboleton
•	androstenedion (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on)		•	prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on)		•	testosteron
•	epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)		•	trenbolon (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT)

a xxxxx xxxxx x podobnou xxxxxxxxx strukturou nebo xxxxxxxxx xxxxxxxxxxxx účinky.

S1.2. XXXXXXX XXXXXXXXXX XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, osilodrostat, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů [SARM, xxxx. andarin, enobosarm (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], xxxxxxx a xxxxxxxxxx.

X2 XXXXXXXXX HORMONY, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X MIMETIKA

ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxxxx látky.

Následující xxxxx x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.

X2.1. ERYTROPOETINY (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

X2.1.1 Xxxxxxxx erytropoetinových xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA)]; EPO- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, peginesatid.

S2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (BAY 85-3934); roxadustat (XX-4592); xxxxxxxxxx (XXX-6548); xenon.

S2.1.3 Xxxxxxxxxx XXXX, např. X-11706.

X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx růstového xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; sotatercept.

S2.1.5 Agonisté xxxxxxxxx opravného xxxxxxxxx, xxxx. xxxxxx EPO; xxxxxxxxxxxxx XXX (CEPO).

S2.2. XXXXXXXXX XXXXXXX X XXXXXX UVOLŇUJÍCÍ FAKTORY

S2.2.1 Xxxxxxx stimulující xxxxxxxxxxx x mužů, xxxx xxxx včetně:

• xxxxxxxx xxxxxxxxxxxx (CG),

• xxxxxxxxxxxx xxxxxx (XX),

• xxxxxx xxxxxxxxxx gonadotropin (XxXX, xxxxxxxxxxx) x xxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x jeho agonistické xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx a xxxxxx uvolňující xxxxxxx, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx hormon (XX), jeho xxxxxxx x xxxxxxxxx, xxxx xxxx xxxxxx:

• xxxxxxx xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx a xxxxxxxxxx,

• xxxxxxxxx růstového xxxxxxx, xxxx. XXX-9604 x xXX 176–191.

X2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, xxxx jiné xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x xxxx analogy, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx x tesamorelin,

• xxxxxxxxxxx růstového xxxxxxx (XXX) x xxxxxx xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x xxxxxxxxxxx],

• xxxxxxx xxxxxxxxxx XX (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, XXXX-5 a XXXX-6].

X2.3. XXXXXXX FAKTORY X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx jiné včetně:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx růstový xxxxxx (XXX)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, mecasermin) x jeho xxxxxxx

• xxxxxxxxxx růstové xxxxxxx (XXX)

• xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX)

• xxxxxxxx-β4 x jeho xxxxxxxx, xxxx. XX-500

• vaskulárně-endoteliární xxxxxxx xxxxxx (VEGF)

a xxxxx růstové faktory xxxx modulátory xxxxxxxxx xxxxxxx xxxxxxxxxxx syntézu/degradaci xxxxxxxx xx xxxxxxx, xxxxxxxx xxxx vazech, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx typy xxxxxxxxx xxxxxx.

X3 BETA-2 AGONISTÉ

ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx selektivní x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;

• xxxxxxxxx formoterol: maximálně xxxxxx dávka 54 xxxxxxxxxx za 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx za 24 hodin.

POZNÁMKA

Přítomnost xxxxxxxxxxx x xxxx v xxxxxxxx xxxxxx než 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx xxxxx x xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že abnormální xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (inhalační) xx xx xxxx xxxxxxx xxxxxxxxx dávky.

S4 XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxxx xxxxx ve xxxxxxx S4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx zařazené xx xxxx S4.3 a X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx hormonové a xxxxxxxxxxx xxxxxxxxxx jsou xxxxxxxx.

X4.1. XXXXXXXXXX AROMATÁZ

Mimo xxxx včetně:

•	2-androstenol (5ɑ-androst-2-en-17-ol)		•	androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on)		•	androsta-3,5-dien-7,17-dion (xxxxxxxxx)
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on)		•	formestan
•	4-androsten-3,6,17 trion (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX A SELEKTIVNÍ XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]

Xxxx jiné včetně:

•	arformoterol		•	indakaterol		•	reproterol		•	tretoquinol (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. LÁTKY ZABRAŇUJÍCÍ XXXXXXXX RECEPTORU XXXXXXXX XXX

Xxxx jiné včetně:

•	protilátky xxxxxxxxxxxxxx aktivin A		•	inhibitory xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx xxxxxxxxx xxxxxxxx IIB, xxxx.:			- xxxxx xxxxxxxxx nebo xxxxxx expresi myostatinu
	- xxxxxxx receptory xxxxxxxx (xxxx. XXX-031)			- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, propeptid xxxxxxxxxx)
•	xxxxxxxxxx xxxxx xxxxxxxxx aktivinu XXX (xxxx. bimagrumab)			- xxxxxxxxxx neutralizující xxxxxxxxx xxxx prekurzory (xxxx. xxxxxxxxxxx, domagro xxxxx, xxxxxxxxxxxxx, stamulumab)

S4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, xxxxxxxx peroxizomovými xxxxxxxxxxx aktivovaného receptoru xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) kyselina xxxxxx (XX1516, XX501516) x xxxxxxxx Xxx-xxxɑ , xxxx. XX9009, XX9011

X4.4.2 xxxxxxxx a xxxxxxxx xxxxxxxx

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX LÁTKY

ZAKÁZANÉ STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx diuretika a xxxxxxxxx xxxxx, xxxxxx xxxxx optických xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxx xxxx včetně:

•  Xxxxxxxxx, xxxx např.:

acetazolamid; amilorid; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Plazmatické xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, např.:

albumin, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;

• Xxxxxxxxxxx;

• Probenecid;

a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x xxxxxxx oftalmologické xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, brinzolamid);

• xxxxxxx xxxxxx xxxxxxxxxxx x zubní anestezii.

POZNÁMKA

Nález xxxxxxxxxxx xxxxxxxx xxxxx xx stanoveným xxxxxxxx xxxxxxx: x formoterolu, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Vzorku Xxxxxxxxx xxxxxxxx nebo případně Xxx Xxxxxxx xx xxxxxxx x diuretikem xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx lokálního xxxxxx xxxxxx inhibitoru xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx felypresinu x xxxxxxxx xxxxxxxxx), bude xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx (AAF), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) na tuto xxxxx xxxxx x xx, xxxxx již xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxxx v xxxx xxxxx jsou Xxxxxxxxxxxx s xxxxxxxx xxxxx x X2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. MANIPULACE S XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je následující:

M1.1. Xxxxxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx x výjimkou xxxxxxxx xxxxxx nebo xxxxxx složek Sportovci xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.

X1.2. Xxxxx zvyšování xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx a modifikované xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xx xxxx hemoglobinu x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx produkty, x výjimkou xxxxxxxxxxx xxxxxxx inhalací.

M1.3. Jakákoliv xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx o xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx a xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx kontrole.

Mimo jiné xxxxxx:

Xxxxxx a/nebo xxxxxx Xxxxxx, např. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx vyšetření.

M3. GENOVÝ X BUNĚČNÝ XXXXXX

X xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx následující:

M3.1. Použití xxxxxxxxxx kyselin nebo xxxxxx xxxxxxx, které xxxxx xxxxxx xxxxxxxx xxxxxx x/xxxx exprese xxxx xxxxxxxxxx xxxxxxxxxxx. Xx mimo xxxx xxxxxxxx technologie xxxxx xxxx, umlčování xxxx x xxxxxxxxxxx přenosů xxxx.

X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx zakázané látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx x xxxxxxxx xxxxx xxxxxxxxx x X6.X, xxx xxxx Nespecifické xxxxx.

Xxxxxxxx xxxxx x xxxx sekci: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)

Všechna xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, xxxx zakázána.

Stimulancia xxxxxxxx:

X6.X: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx a jeho xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx x xxxx analogy, např. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (adrenalin)4)		•	metylnaftidát [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky

VÝJIMKY

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, očního xxxx xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, klonazolin, fenoxazolin, xxxxxxxxxxx, nafazolin, oxymetazolin, xxxxxxxxxx, tramazolin, xxxxxxxxxxxxx) x stimulancia xxxxxxxx xx Monitorovacího xxxxxxxx 2024⁵⁾.

X7 NARKOTIKA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: diamorfin (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx optických xxxxxxx, xxxx. d- x l, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 KANABINOIDY

ZAKÁZANÉ XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x této xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x syntetické kanabinoidy xxxx xxxxxxxx, např.

• x konopí (xxxxx, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• xxxxxxxx x xxxxxxxxxx tetrahydrokanabionoly (XXX)

• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Všechny glukokortikoidy xxxx xxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, perorální [včetně xxxxxxxxxx (např. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Jiné xxxxxxx xxxxxx (včetně xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) nejsou zakázány, xxxxx xx používají x rámci xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky.

Beta-blokátory xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx sportech Xxx Xxxxxxx x xxx xx xx xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• lyžování/snowboarding (XXX) – xxxxx xx xxxxxx, xxxxxxxxxxx xxxxx / X-xxxxx x xxxxxxxxx X-xxxxx / xxx xxx

• automobilový xxxxx (XXX)

• xxxxxxxx xxxxxx (CMAS)* v xxxxxxxxxxxx volného xxxxxxxx, xxxx xxxxxxxx x xxxxxxx xx xxxx

• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• xxxxx (XXX)

• xxxx (IGF)

• xxxxxxxx (XXX)

• střelba (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx soutěž

Mimo xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx smlouvy x xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x jeho x-xxxxxx: je xxxxxxxx xxxxx při xxxxxxxxxxx x xxxx xxxxx xxx 5 xxxxxxxxxx x 1 ml.

²⁾ xxxxxxxxxxxxx: zakázaný xxxxx xxx xxxxxxxxxxx v xxxx xxxxx xxx 150 mikrogramů x 1 ml.

³⁾ xxxxxxx x metylefedrin: xxxxxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx.

⁴⁾ xxxxxxxxx (xxxxxxxxx): není xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, nebo xxxxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx.

⁵⁾ bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: xxxx xxxxx xxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx č. 19/2025 Xx. xxxxx xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx právních předpisů x odkazech xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx